Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.78 |
| ▸ | PPARG | P37231 | 3/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.78 |
| ▸ | THRB | P10828 | 10/20 | 0.74 |
| ▸ | THRA | P10827 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | PCNA | P12004 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | GABRP | O00591 | 1/20 | 0.74 |
| ▸ | GABRD | O14764 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | F2 | P00734 | 1/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.74 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diiodothyronine SCHEMBL29410661 | 1.00 | MEN1 (0.78) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL3177460 | 1.00 | MEN1 (0.78) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL935895 | 1.00 | MEN1 (0.78) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL29374527 | 1.00 | MEN1 (0.78) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL31613058 | 1.00 | MEN1 (0.78) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL1741359 | 0.95 | MEN1 (0.71) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL2513511 | 0.95 | MEN1 (0.71) | MEN1KMT2APPARGBLMNR1I2 | |
| Diiodothyronine SCHEMBL29827067 | 0.93 | MEN1 (0.67) | MEN1KMT2APPARGBLMNR1I2 | |
| SCHEMBL14574802 | 0.93 | THRB (0.70) | MEN1KMT2APPARGBLMNR1I2 | |
| SCHEMBL14574800 | 0.93 | THRB (0.70) | MEN1KMT2APPARGBLMNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| CN-107840813-B | Process for the preparation of sulfated derivatives of 3, 5-diiodo-O- [ 3-iodophenyl ] -L-tyrosine | 伯拉考成像股份公司 | 2020-12-22 | — | — | CN | claimed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | claimed |
| EP-3621602-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | Musli Thyropeutics Ltd. (IL) | 2020-03-18 | — | — | EP | claimed |
| WO-2018207171-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2018-11-15 | — | — | WO | claimed |
| EP-2694471-B1 | PROCESS FOR THE PREPARATION OF A SULFATED DERIVATIVE OF 3,5-DIIODO-O-[3-IODOPHENYL]-L-TYROSINE | BRACCO IMAGING SPA (IT) | 2017-08-02 | — | — | EP | claimed |
| US-9328331-B2 | Compositions and methods for promoting beta cell maturity | JOSLIN DIABETES CENTER, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20120141436-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-03-17 | — | — | US | claimed |
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-02-03 | — | — | US | claimed |
| WO-2002089917-A2 | DERMATOLOGICAL FORMULATIONS | KARO BIO AB (SE) | 2002-11-14 | — | — | WO | claimed |
| US-20020123521-A1 | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds | KOO, CATHERINE, DR | 2002-09-05 | — | — | US | claimed |
| US-6380255-B1 | TOPICALLY APPLYING TO SKIN THYROID HORMONE COMPOUND TOGETHER WITH A BASE FOR THERAPY OF SKIN ATROPHY | KARO BIO AB (SE) | 2002-04-30 | — | — | US | claimed |
| WO-2002005834-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE AGONIST COMPOUNDS FOR TREATING DERMIS CONDITIONS | KARO BIO AB (SE) | 2002-01-24 | — | — | WO | claimed |
| US-6221911-B1 | REDUCING SUBCUTANEOUS FAT DEPOSITS IN A SUBJECT; IMPROVING THE SKIN CONDITION OF A SUBJECT | KARO BIO AB (SE) | 2001-04-24 | — | — | US | claimed |
| EP-0831769-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | KARO BIO AB (SE) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040048-A9 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | — | 1997-03-27 | — | — | WO | claimed |
| WO-1996040048-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | KARO BIO AB (SE) | 1996-12-19 | — | — | WO | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | TPO, HSD3B2, THRB | MEN1 692/4885KMT2A 2483/4885PPARG 189/4885 |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | MEN1 4231/4885KMT2A 4248/4885PPARG 1073/4885 |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | TPO, TSHR, THRA | MEN1 301/4885KMT2A 4327/4885PPARG 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.